Shorter time to discontinuation due to treatment failure in people living with HIV switched to dolutegravir plus either rilpivirine or lamivudine compared with integrase inhibitor-based triple therapy in a large Spanish cohort

Ramón Teira1, Helena Diaz-Cuervo1, Filipa Aragão3,4, Manuel Castaño5, Alberto Romero6, Bernardo Roa7, Marta Montero8, Maria José Galindo8, Maria Jose Muñoz-Sánchez10, Nuria Espinosa11, Joaquim Peraire12, Elisa Martínez13, Belén de la Fuente14, Pere Domingo15, Elisabeth Deig16, María Dolores Merino17, Paloma Geijo18, Vicente Estrada19, María Antonia Sepúlveda20, Josefina García21, Juan Berenguer22, Adriá Currán23

1Hospital de Sierrallana, Torrelavega, Spain; 2Gilead Sciences, MAOR, London, UK; 3Maple Health Group, New York, USA; 4NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisboa, Portugal; 5Hospital Regional Universitario de Málaga, Málaga, Spain; 6Hospital Universitario de Puerto Real, Puerto Real, Spain; 7Hospital General de Castellón, Castellón, Spain; 8Hospital Universitario y Politécnico La Fe, Valencia, Spain; 9Hospital Clínico Universitario de Valencia, Valencia, Spain; 10Hospital Universitario de Basurto, Bilbao, Spain; 11Hospital Universitario Virgen del Rocío, Sevilla, Spain; 12Hospital Universitario Joan XXIII, Tarragona, Spain; 13Complejo Hospitalario de Albacete, Albacete, Spain; 14Hospital Universitario de Cabueñes, Gijón, Spain; 15Hospital de al Santa Pau, Barcelona, Spain; 16Hospital General de Granollers, Granollers, Spain; 17Hospital Juan Ramón Jiménez, Huelva, Spain; 18Hospital Virgen de la Luz, Cuenca, Spain; 19Hospital Clinico de San Carlos, Madrid, Spain; 20Hospital Virgen de la Salud, Toledo, Spain; 21Hospital de Santa Lucía, Cartagena, Spain; 22Hospital Gregorio Marañón, Madrid, Spain; 23Hospital Universitari Vall d’Hebrón, Barcelona Spain

CORRESPONDING AUTHOR:

Ramón Teira
Service of Internal Medicine
Hospital de Sierrallana
39300 Torrelavega, Spain
Telephone +34942847400; Fax +34942847501
E-mail: ramon.teira1@gmail.com

¶These authors contributed equally to this work.

&These authors also contributed equally to this work.
**Table S1: Reasons for switch from three-drug regimens or two-drug regimens during the study period.**

| Reason, n (%)      | Three-Drug Regimens (n=5047) | Two-Drug Regimens (n=617) |
|--------------------|------------------------------|---------------------------|
| Total switched     | 984 (19.5)                   | 99 (16.0)                 |
| Treatment failure  | 83 (8.4)                     | 18 (18.2)                 |
| Of which virologic failure | 57 (5.8)            | 11 (11.1)                 |
| Adverse events     | 131 (13.3)                   | 12 (12.1)                 |
| Intolerance        | 32 (3.3)                     | 7 (7.1)                   |
| Avoiding long-term toxicity | 43 (4.4)            | 3 (3.0)                   |
| Simplification     | 221 (22.5)                   | 8 (8.1)                   |
| Other              | 474 (48.2)                   | 51 (51.5)                 |

**Figure S1. Reasons for discontinuation from three-drug regimens or two-drug regimens during the study period.**